Kyverna Therapeutics, Inc. (KYTX): Valuation
TTM figures as of June 30, 2026
Kyverna Therapeutics, Inc. trades at a -35.36% free-cash-flow yield. That FCF yield is higher than 52% of its own month-end history back to 2024.
Earnings yield -34.00%. Net cash $174.4M.
31 month-end valuation observations are on file, starting February 2024.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is KYTX cheap versus its own history?
Kyverna Therapeutics, Inc. trades at a -35.36% free-cash-flow yield. That FCF yield is higher than 52% of its own month-end history back to 2024.
What is KYTX's free-cash-flow yield?
Kyverna Therapeutics, Inc. currently yields -35.36% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.